ISSN (Online): 2321-3418
server-injected
Medical Sciences and Pharmacy
Open Access

Targeting the Mitochondrial Permeability Transition Pore: A Translational Approach to Prevent Myocardial Reperfusion Injury in Delayed Percutaneous Coronary Intervention

,
DOI: 10.18535/ijsrm/v14i01.mp03· Pages: 2419-2421· Vol. 14, No. 01, (2026)· Published: January 13, 2026
PDF
Views: 635 PDF downloads: 301

Abstract

Timely revascularization is the cornerstone of limiting ischemic cell death in acute myocardial infarction (MI) (1). However, delayed percutaneous coronary intervention (PCI) paradoxically poses a significant threat to the myocardium, leading to lethal reperfusion injury—a major clinical problem contributing to adverse outcomes despite successful epicardial reperfusion (2). Microvascular injury resulting from delayed reperfusion, first documented in the 1960s, significantly exacerbates myocardial injury (3). The pathogenesis of lethal reperfusion injury is driven by three central paradoxes: the calcium paradox, involving a pathological surge in intracellular calcium; the oxygen paradox, characterized by a burst of reactive oxygen species (ROS); and the pH paradox, marked by the rapid normalization of intracellular pH (4). These converge to induce mitochondrial permeability transition pore (MPTP) opening, resulting in mitochondrial damage and cardiomyocyte death (5). Despite elucidation of these mechanisms in experimental models, translation to clinical cardioprotection has been challenging (6). This review explores the mechanistic pathways of reperfusion injury, discusses the failures and promises of therapeutic strategies, and highlights future translational directions for protecting the myocardium in the context of delayed PCI. Therefore, overcoming translational challenges by developing targeted combination therapies and refining patient selection based on individual pathophysiology is the crucial next step to harness the therapeutic potential of MPTP inhibition and significantly improve outcomes in delayed PCI (7).

Keywords

Myocardial Reperfusion InjuryMitochondrial Permeability Transition PorePercutaneous Coronary Int

References

  1. Ibanez B, et al. Evolving therapies for myocardial ischemia/reperfusion injury. J Am Coll Cardiol. 2015;65(14):1454-1471.Google Scholar ↗
  2. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med. 2007;357(11):1121-1135.Google Scholar ↗
  3. Kloner RA, Ganote CE, Jennings RB. The "no-reflow" phenomenon after temporary coronary occlusion in the dog. Am Heart J. 1985;109(2):305-318.Google Scholar ↗
  4. Hausenloy DJ, Yellon DM. The mitochondrial permeability transition pore: its fundamental role in mediating cell death during ischaemia and reperfusion. J Mol Cell Cardiol. 2003;35(4):339-341.Google Scholar ↗
  5. Halestrap AP, Richardson AP. The mitochondrial permeability transition: a current perspective on its identity and role in ischaemia/reperfusion injury. J Mol Cell Cardiol. 2015;78:129-141.Google Scholar ↗
  6. Hausenloy DJ, et al. Translating cardioprotection for patient benefit: position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology. Cardiovasc Res. 2013;98(1):7-27.Google Scholar ↗
  7. Ong SB, et al. Inhibiting Mitochondrial Fission Protects the Heart Against Ischemia/Reperfusion Injury. Circulation. 2010;121(18):2012-2022.Google Scholar ↗
  8. O'Gara PT, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction. J Am Coll Cardiol. 2013;61(4):e78-e140.Google Scholar ↗
  9. Terkelsen CJ, et al. System delay and mortality among patients with STEMI treated with primary percutaneous coronary intervention. JAMA. 2010;304(7):763-771.Google Scholar ↗
  10. Braunwald E, Kloner RA. Myocardial reperfusion: a double-edged sword?. J Clin Invest. 1985;76(5):1713-1719.Google Scholar ↗
  11. Niccoli G, et al. Myocardial no-reflow in humans. J Am Coll Cardiol. 2009;54(4):281-292.Google Scholar ↗
  12. Anderson JL, Morrow DA. Acute Myocardial Infarction. N Engl J Med. 2017;376(21):2053-2064.Google Scholar ↗
  13. Levine GN, et al. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease. J Am Coll Cardiol. 2016;68(10):1082-1115.Google Scholar ↗
  14. Bøtker HE, et al. Practical guidelines for rigor and reproducibility in preclinical and clinical studies on cardioprotection. Basic Res Cardiol. 2018;113(5):39.Google Scholar ↗
  15. Janse MJ, Wit AL. Electrophysiological mechanisms of ventricular arrhythmias resulting from myocardial ischemia and infarction. Physiol Rev. 1989;69(4):1049-1169.Google Scholar ↗
  16. Bolli R, Marbán E. Molecular and cellular mechanisms of myocardial stunning. Physiol Rev. 1999;79(2):609-634.Google Scholar ↗
  17. Heusch G. Myocardial ischaemia-reperfusion injury and cardioprotection in perspective. Nat Rev Cardiol. 2020;17(12):773-789.Google Scholar ↗
  18. García-Dorado D, et al. Calcium-mediated cell death during myocardial reperfusion. Cardiovasc Res. 2012;94(2):168-180.Google Scholar ↗
  19. Zweier JL, Talukder MA. The role of oxidants and free radicals in reperfusion injury. Cardiovasc Res. 2006;70(2):181-190.Google Scholar ↗
  20. Cohen MV, Downey JM. Ischaemic postconditioning: from bench to bedside. Cardiovasc Res. 2008;79(1):3-4.Google Scholar ↗
  21. Murphy E, Steenbergen C. Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury. Physiol Rev. 2008;88(2):581-609.Google Scholar ↗
  22. Halestrap AP. Calcium, mitochondria and reperfusion injury: a pore way to die. Biochem Soc Trans. 2006;34(Pt 2):232-237.Google Scholar ↗
  23. Avkiran M, Marber MS. Na(+)/H(+) exchange inhibitors for cardioprotective therapy: progress, problems and prospects. J Am Coll Cardiol. 2002;39(5):747-753.Google Scholar ↗
  24. Gustafsson ÅB, Gottlieb RA. Heart mitochondria: gates of life and death. Cardiovasc Res. 2008;77(2):334-343.Google Scholar ↗
  25. Reffelmann T, Kloner RA. The no-reflow phenomenon: A basic mechanism of myocardial ischemia and reperfusion. Basic Res Cardiol. 2006;101(5):359-372.Google Scholar ↗
  26. Hausenloy DJ, Yellon DM. Ischaemic conditioning and reperfusion injury. Nat Rev Cardiol. 2016;13(4):193-209.Google Scholar ↗
  27. Reimer KA, Lowe JE, Rasmussen MM, Jennings RB. The wavefront phenomenon of ischemic cell death. 1. Myocardial infarct size vs duration of coronary occlusion in dogs. Circulation. 1977;56(5):786-794.Google Scholar ↗
  28. Braunwald E. The treatment of acute myocardial infarction: the past, the present, and the future. Eur Heart J Acute Cardiovasc Care. 2012;1(1):9-12.Google Scholar ↗
  29. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation. 1990;81(4):1161-1172.Google Scholar ↗
  30. Hausenloy DJ, et al. Effect of remote ischaemic conditioning on clinical outcomes in patients with acute myocardial infarction (CONDI-2/ERIC-PPCI): a single-blind randomised controlled trial. Lancet. 2019;394(10207):1415-1424.Google Scholar ↗
  31. Cung TT, et al. Cyclosporine before PCI in Patients with Acute Myocardial Infarction. N Engl J Med. 2015;373(11):1021-1031.Google Scholar ↗
  32. Lincoff AM, et al. Inhibition of the sodium-hydrogen exchanger with cariporide to prevent myocardial infarction in high-risk ischemic situations. Main results of the GUARDIAN trial. Circulation. 2000;102(25):3032-3038.Google Scholar ↗
  33. Eitel I, et al. Prognostic value and determinants of a hypointense infarct core in T2-weighted cardiac magnetic resonance in acute reperfused ST-elevation myocardial infarction. Circ Cardiovasc Imaging. 2011;4(4):354-362.Google Scholar ↗
  34. Ferdinandy P, et al. Interaction of risk factors, comorbidities, and comedications with ischemia/reperfusion injury and cardioprotection by preconditioning, postconditioning, and remote conditioning. Pharmacol Rev. 2014;66(4):1142-1174.Google Scholar ↗
  35. Garcia-Dorado D, et al. Novel therapeutic strategies for the management of myocardial ischemia/reperfusion injury: where are we going?. Trends Cardiovasc Med. 2017;27(1):1-7.Google Scholar ↗
  36. Argaud L, et al. Specific inhibition of the mitochondrial permeability transition prevents lethal reperfusion injury. J Mol Cell Cardiol. 2005;38(2):367-374.Google Scholar ↗
  37. Elrod JW, Molkentin JD. Physiologic functions of cyclophilin D and the mitochondrial permeability transition pore. Circ J. 2013;77(5):1111-1122.Google Scholar ↗
  38. White SK, et al. Measuring myocardial salvage. Cardiovasc Res. 2012;94(2):266-275.Google Scholar ↗
  39. Heusch G, et al. Cardiovascular remodelling in coronary artery disease and heart failure. Lancet. 2014;383(9932):1933-1943.Google Scholar ↗
  40. Davidson SM, et al. Multitarget Strategies to Reduce Myocardial Ischemia/Reperfusion Injury: JACC Review Topic of the Week. J Am Coll Cardiol. 2019;73(1):89-99.Google Scholar ↗
Author details
İlyas Mammadyarov
✉ Corresponding Author
👤 View Profile →
Babak Bahrami
👤 View Profile →